Cosmetic Neurotoxin Market Study

Cosmetic neurotoxins are still growing in 2026 even though the broader aesthetics market has flattened or slowed. Neurotoxins are relatively affordable, act quickly, and do not lock patients into a permanent result. That makes them easier for first-time patients to try than many other aesthetic treatments. For practices, they also bring patients back regularly and often open the door to other procedures, including fillers, skin rejuvenation, and energy-based treatments.

Consumer demand remains strong, which has drawn more competition into this market sector. Allergan, Galderma, and Merz Aesthetics have long dominated the field, but manufacturers from South Korea, China, and Europe are pressing into North America and other regions. Hugel has already commercialized Letybo in the U.S. through BENEV, while MedTox and Daewoong continue to expand globally. The same pattern is unfolding across Asia-Pacific, Latin America and the Middle East, where manufacturers are competing for a share of emerging and still-untapped markets.